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Abstract
Objective—Patients with serious mental illness (SMI) often have comorbid cardiometabolic 
conditions (CMCs) that may increase the number of prescribers involved in treatment. This study 
examined whether patients with SMI (depression and schizophrenia) and comorbid CMCs 
experience greater discontinuity of prescribing than patients with CMCs alone.
Methods—2009 Medicaid data were used to compare number and types of prescribers (primary 
care, cardiometabolic, psychiatric, other) in individuals with 1-3 CMCs (diabetes, hypertension, 
dyslipidemia) alone (n=76,451); with CMC and schizophrenia (n=6,507); and with CMC and 
depression (n=23,510) and the degree of prescribing within a provider’s area of specialty.
Results—44%, 61%, and 71% of individuals with CMCs only, with CMCs and schizophrenia, 
and with CMCs and depression had medications from these classes prescribed by 5 or more 
providers respectively. More than 35% of patients with CMCs alone or CMCs and schizophrenia 
had prescriptions provided by 3 or more PCP providers, which increased to 49.1% for patients 
with CMCs and depression. In the schizophrenia cohort, 29% of antipsychotics were PCP-
prescribed while psychiatrists prescribed 10%, 9%, and 9% of antihypertensive, 
antihyperlipidemic, and antidiabetic medications respectively.
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Conclusions—The presence of SMI increases the number of prescribers treating individuals 
with CMCs. The impact of this fragmentation in medication management on health outcomes is 
unknown.
Suggested Keywords
Continuity of care; mental health; chronic disease; diabetes; hypertension
Introduction
Patients with multiple comorbid conditions (MCCs) have been shown to have an increased 
risk of adverse health outcomes, both because of the compounding risk of the conditions 
themselves and the complexity of healthcare required to manage multiple conditions (1). 
However, the ways in which health systems compound or mitigate the MCC-outcome 
association is poorly understood. Adults with MCCs often see different providers, including 
primary care and multiple specialists (2). As a result, their medical care is highly fragmented 
(3). Lacking a usual source of care is associated with higher rates of medication-related 
problems, emergency department (ED) visits and hospitalizations (4–11).
Most continuity of care studies in MCC populations focus on continuity with providers and 
not continuity with prescribers. Continuity of care is a complex construct that involves 
longitudinal continuity, informational continuity and management continuity(3). For this 
study, we define continuity of prescribing as a measure of longitudinal continuity in which a 
patient fills prescriptions from the same provider over time, which is operationally distinct 
from informational continuity (the availability of accurate and current patient information) 
or management continuity (care plan agreed upon by all providers and the patient). 
Conceptually, continuous prescribing by a single physician is thought to result in better 
health outcomes through more appropriate medication use, reductions in drug duplications, 
fewer drug-drug interactions, and better medication adherence (12). In addition, it is 
operationally distinct from measures that look at office visits to different physicians over 
time in that it directly assesses the provision of a medical intervention in the form of a 
prescription. Prior studies have demonstrated better medication adherence (13) and lower 
emergency department visits and inpatient hospitalizations (14) in patients receiving 
prescriptions from a single provider than patients with multiple prescribers. However, these 
studies are limited to a single Veterans Affairs Medical Center (VAMC) and only looked at 
patients with one or more of four cardiometabolic conditions (hypertension, hyperlipidemia, 
diabetes, and congestive heart failure). These studies did not look at prescriber specialty and 
did not examine the extent to which providers prescribed within their specialty. Although the 
involvement of specialists in medication management may be clinically appropriate in 
certain situations, continuity of care may also be compromised when more than one provider 
is involved in the prescribing process (15).
Continuity of care may be a particular challenge in individuals with severe mental illness 
(SMI) given high rates of comorbidity with cardiometabolic health conditions. Baseline rates 
of diabetes, hypertension, and hyperlipidemia in patients with schizophrenia entering the 
Clinical Antipsychotic Trials of Intervention Effectiveness were 11%, 33%, and 47% 
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respectively (16). Despite their prevalence, the cardiometabolic health conditions of patients 
with SMI have been shown to be inadequately treated (17). Among the reasons cited for this 
under-treatment includes issues of care coordination, particularly between primary care and 
psychiatric providers (18).
Prescriber continuity is an important concept in the management of patients with MCCs who 
typically see multiple providers (19, 20) and take multiple medications (21, 22), which puts 
them at higher risk of adverse drug events (23). Of the few studies examining continuity of 
prescribing in patients with MCC only one study to our knowledge has examined this issue 
in patients with SMI and this study limited its analysis to the effect of prescriber continuity 
on antipsychotic treatments (24). Continuity of prescribing takes on even greater importance 
in patients with SMI given prior evidence that better care continuity in this population has 
been associated with better quality of life, better community functioning, lower severity of 
symptoms, and greater service satisfaction (27). A patient-centered understanding of 
continuity of care in the context of medication management in patients with serious mental 
illness requires consideration of prescribers of medications to manage SMI and the 
discordant conditions that are highly prevalent and often are managed by non-psychiatric 
specialists (16).
The objective of this study is to describe patient characteristics and continuity in the 
prescribing process by measuring patterns in the number and type of prescribers providing 
prescriptions to Medicaid beneficiaries with cardiometabolic health conditions with and 
without comorbid schizophrenia or depression. In addition to continuity of prescribing by 
the same prescriber over time, this analysis also examines the scope of prescribing within 
and outside of providers’ area of specialty, which is an important first step in identifying 
prescribing scenarios that may minimize the risk for adverse drug events and poor health 
outcomes.
Methods
Study Design and Data
This study used a retrospective cross-sectional study design to examine patterns of 
prescribing among patients with 1–3 cardiometabolic health conditions (diabetes, 
hypertension, and/or hyperlipidemia). We stratified the cohort of Medicaid enrollees into 
three groups: 1) enrollees with claims diagnoses for one or more of the three 
cardiometabolic conditions alone (no schizophrenia or depression), 2) enrollees with claims 
diagnoses for one or more cardiometabolic conditions and comorbid schizophrenia, and 3) 
enrollees with claims diagnoses for one or more cardiometabolic condition and comorbid 
depression without a diagnosis of schizophrenia. These comparison groups were established 
to test the hypothesis that having a discordant condition, such as a serious mental illness, 
would increase the number of prescribers in individuals with cardiometabolic conditions. 
That is, patients without an SMI would have little need for medications from a psychiatrist, 
while patients with depression or schizophrenia might require ongoing medication 
management by a psychiatrist. As a result, clinically appropriate referral to a psychiatrist 
could result in unintended fragmentation in these patients’ overall medication management. 
Examination of these three cohorts allowed us to examine if prescribing patterns differed for 
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patients with and without comorbid SMI and whether prescribing patterns differed by 
comorbid depression or schizophrenia. We used 2009 Medicaid Analytical Extract (MAX) 
claims from NC, CO, VT and KY. These states represent diverse geographical regions of the 
U.S. and were identified as having low rates of missing provider information by the Centers 
for Medicare & Medicaid Services (CMS).
Inclusion/Exclusion Criteria
From an initial data pull of 515,466 individuals across the 4 state Medicaid programs, we 
included 244,973 individuals aged 18 to 64 with one or more inpatient or two or more 
outpatient claims with ICD-9-CM codes for diabetes, hypertension, hyperlipidemia, 
depression, or schizophrenia (Supplemental Appendix A). Of these patients, 177,774 
patients had continuous enrollment during calendar year 2009. We then excluded 15,394 
individuals dually enrolled in Medicare or private insurance to ensure data capture given that 
claims not reimbursed through Medicaid are missing in this population. We restricted our 
sample to 137,177 patients using one or more medications to manage each individual 
condition (Supplemental Appendix B). Of these patients, 233 who have unidentified 
providers and subsequently, 30,476 who do not have a CMC were also excluded. The final 
cohort included 76,451 patients with one or more cardiometabolic health conditions without 
schizophrenia or depression, which we define as the cardiometabolic only cohort 
(Supplemental Appendix C). In addition, 6,507 patients had one or more cardiometabolic 
conditions and comorbid schizophrenia (schizophrenia cohort) and 23,510 had one or more 
cardiometabolic conditions and comorbid depression (depression cohort).
Prescriber Variable Definition
We defined both the annual count and types of prescribers for the three cardiometabolic 
conditions and two mental health conditions. Prescribers of medications used to manage 
conditions beyond these 5 conditions of interest were not considered. Prescription claims 
were used to identify the prescriber of record for each medication. For the 31.4% of claims 
missing prescriber identifiers, the outpatient record most recent to the new prescription fill 
was used to identify the prescriber. Among the new prescriptions without a prescriber 
identifier, 57.0% matched an office visit within 1 day of the prescription, 74.3% matched 
within 7 days, and 90.7% matched within 30 days. 9.3% of prescriptions did not match to a 
prescriber within 30 days and were excluded in our final analysis.
Provider specialty was identified using National Provider Identifier (NPI) taxonomy codes. 
Specifically, prescribers were grouped into four specialty categories: (1) primary care (e.g., 
family medicine provider, internal medicine provider, or nurse practioners), (2) 
cardiometabolic (e.g., cardiologist, endocrinologist, or diabetes & metabolism specialist), (3) 
psychiatric (e.g., psychiatrist or other psychiatric/mental/health specialist), or “other” area of 
practice (e.g., general acute care hospital provider, emergency medicine, unspecified 
specialist, and home health). Specialty taxonomy information was missing from 6.5% of 
claims and these claims were not included in our final analysis.
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Descriptive Variables
We examined differences in enrollee demographic information across each of the cohorts of 
interest. Enrollee demographic variables included continuous age, sex, and race (white, 
black, and other/missing). The other racial category was created given the infrequency of 
reporting races other than white or black. We also examined Medicaid enrollment variables 
including enrollment in behavioral health managed care plans, receipt of primary care case 
management in the Medicaid program, and blind/disabled versus other enrollment status in 
Medicaid. To examine the full scope of comorbid conditions an individual may have, we 
also calculated the Chronic Disease Payment Score for each person (25) (26).
Analysis
First, differences in characteristics between enrollees in the depression and schizophrenia 
cohorts were compared to individuals in the cardiometabolic only cohort using two-sided t-
tests and chi-squared tests. Second, we describe the number and types of providers 
prescribing medications across each cohort. Third, we examined the combination of 
prescriber specialties of Medicaid enrollees to examine the proportion of patients seeing one, 
two, three, or all four specialty types. Finally, we examined the scope of prescribing by area 
of specialty by categorizing the proportion of new prescriptions across the 5 conditions of 
interest (antihyperlipidemics, antidiabetics, antihypertensives, antidepressants, and 
antipsychotics) written by a PCP, psychiatric specialist, cardiometabolic specialist, or other 
specialty prescriber. The purpose of this analysis was to examine the proportion of 
prescriptions written within or outside of a prescriber’s area of specialty. For example, we 
expected that psychiatric providers might commonly be prescribing anti-psychotics and anti-
depressants for patients with comorbid schizophrenia or depression, but would be less likely 
to prescribe medications to manage diabetes, hypertension or dyslipidemia.
This study was approved by the Institutional Review Boards of each author’s corresponding 
institution.
Results
Patient Characteristics
Table 1 presents demographic comparisons between the schizophrenia and depression 
cohorts relative to the cardiometabolic only cohort. Where noted, comparisons between the 
depression and schizophrenia cohorts not presented in Table 1 are also highlighted with 
corresponding p-values herein. Compared to the cardiometabolic only cohort, the depression 
cohort had more (64.6 vs 77.1%) (p<0.001) and the schizophrenia cohort had fewer female 
Medicaid enrollees (64.6 vs 58.7%) (p<0.001). In addition, the depression cohort had more 
white (66.8%) (p<0.001) and the schizophrenia cohort had fewer white (47.4%) (p<0.001) 
enrollees than the cardiometabolic only cohort (56.2%). There was also a higher rate of 
individuals with blind/disabled Medicaid enrollment in the schizophrenia cohort (97.3%) 
than in either the cardiometabolic only (72.5%) (p<0.001) or depression (73.9%) cohorts 
(p<0.001). Among adults in the cardiometabolic only cohort, 45.5% had one, 38.1% had 
two, and 16.4% had all three cardiometabolic conditions. Among the cohort with 
schizophrenia, 34.8% of individuals had comorbid depression; 47.8% had only one 
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cardiometabolic condition, 36.0% had two and 16.1% had all three cardiometabolic 
conditions. Among the depression cohort, 50.6% of patients had only one comorbid 
cardiometabolic condition, 34.0% had 2 conditions and 15.5% had all three cardiometabolic 
comorbidities.
Number of Prescribers by Specialty Seen by Medicaid Enrollees with Multiple Chronic 
Conditions
Table 2 provides a description of the number of prescribers from whom patients are 
receiving medications. Prescribing by a single provider over a one year period was 
uncommon in all cohorts, ranging from 9.6%, 4.3%, and 2.7%, respectively. On the other 
hand, prescribing by 5 or more prescribers ranged from 44.4%, 61.0%, and 70.7% in these 
same patients, respectively. In all three cohorts, most patients had a prescription written by at 
least one primary care provider (94% in the cardiometabolic only cohort, 93% in the 
schizophrenia cohort and 96% in the depression cohort). Additionally, compared to 49.1% of 
patients in the depression cohort having prescriptions written by 3 or more PCPs, only 
36.5% of patients in the cardiometabolic only cohort (p < 0.001) and 35.4% of patients in 
the schizophrenia cohorts (p< 0.001) had prescriptions written by 3 or more PCPs.
Interestingly, few patients in any cohort were prescribed medication by a cardiometabolic 
specialist, with a lower proportion in the schizophrenia cohort (10.3%) than in the 
cardiometabolic only (16.1%) (p<0.001) or depression cohorts (17.1%) (p<.0.001). Not 
surprisingly, patients in the schizophrenia and depression cohorts were more likely to have a 
prescription written by a psychiatric specialist (66.9% (p<0.001) and 38.9% (p<0.001), 
respectively) than patients in the cardiometabolic only cohort (5.4%). Among patients in the 
depression cohort with a prescribing psychiatrist, 66.8% had a prescription written by only 
one psychiatric prescriber, while 24.3% and 8.9% had a prescription written by 2 or 3 or 
more psychiatric specialty providers respectively. In contrast, among patients in the 
schizophrenia cohort with a prescribing psychiatrist, 51.5% had a prescription written by a 
single psychiatric provider while 31.1% and 17.5% of patients had prescriptions written by 2 
or 3 or more providers, respectively.
Combinations of Prescriber Specialty Prescribing to Medicaid Enrollees with Multiple 
Chronic Conditions
Table 3 examines further the types of providers from whom individuals in in each of the 
three cohorts received prescriptions. Patients with cardiometabolic conditions alone were the 
most likely cohort to receive prescriptions from only one type of provider (24.4% of 
patients) with the most common type of provider being a PCP. In contrast, 8.9% (p<0.001) 
and 8.7% (p<0.001) of patients in the schizophrenia and depression cohorts, respectively, 
received prescriptions from saw only one type of provider. In all cohorts, among the 
subgroup of patients receiving prescriptions from only one type of provider, the most 
common provider type to prescribe medications was a PCP (81.2% of the cardiometabolic 
only cohort, 70.1% of the schizophrenia cohort, and 78.9% of the depression cohort). Most 
patients in the cardiometabolic only cohort received prescriptions from two provider types 
(59.6%) during 2009, with the most common combination of provider types being a PCP 
and “other” specialty (92.9% of patients seeing two provider types). Similarly, 47.5% of 
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patients in the depression cohort received prescriptions from two or more provider types 
with the most common combination (88.7%) being a PCP and “other” specialist. In the 
schizophrenia cohort, 50.6% of patients received prescriptions from three or more provider 
types with the most common combination being a PCP, psychiatric specialist, and other 
specialist (93.0% of patients receiving prescriptions from three or more provider types).
Scope of Prescribing by Provider Specialty
Table 4 presents the prescription level analysis of prescribing by provider specialty for each 
class of medication across the three cohorts. In each cohort, the most common prescriber of 
cardiometabolic medications was a PCP. Interestingly, prescribing of cardiometabolic 
medications by a cardiometabolic specialist was slightly higher in the cardiometabolic only 
cohort (5.5–6.3%) and depression cohort (5.4–6.2%) than in the schizophrenia cohort (2.8 - 
3.3%). In addition, cardiometabolic medication prescribing by a psychiatrist was higher in 
patients with schizophrenia (8.5 - 10.3%) than among patients with depression (2.3 - 2.9%). 
In the schizophrenia cohort, medications for hypertension, hyperlipidemia, and diabetes 
were prescribed by a psychiatrist 10.3%, 8.5%, and 9.2% of the time, respectively. 
Antipsychotics and antidepressants in patients with schizophrenia were most frequently 
prescribed by psychiatrists (46.6% and 44.1%, respectively) but were also prescribed by 
PCPs (28.8% and 30.5%, respectively). In patients with depression, the percentage of 
antipsychotics and antidepressants prescribed by a psychiatrist also was common (42.5% 
and 30.2%, respectively) as was prescribing of these medications by PCPs (31.2% and 
43.6%, respectively).
Discussion
This study examined continuity of care in the context of medication management for 
patients with SMI and cardiometabolic conditions. Our results show that having a single 
provider manage medications in patients with multiple chronic conditions is the exception 
and not the rule. While nearly all individual patients in each cohort had at least one 
prescription written by a PCP over the one-year study period, the majority of patients 
received prescriptions by 2 or more PCPs. In addition, specialty prescribing was common, 
particularly for Medicaid enrollees with comorbid schizophrenia or depression.
This study extends prior work that examined the types of prescribers involved in the 
treatment of patients across different cohorts (13, 14, 24). Expectedly, the presence of 
schizophrenia or depression yielded a higher probability that an individual had a prescription 
written by a psychiatrist. However, prescribing by a cardiometabolic specialist was lower in 
patients with cardiometabolic conditions schizophrenia (10%) than in patients with 
cardiometabolic conditions alone (16%) or patients with depression and cardiometabolic 
conditions (17%). Although continuity of care is associated with better health outcomes, it 
has also been argued that perfect continuity of care by one single provider may not be ideal 
and many patients may benefit from care provided by a specialist (28, 29). Given the lower 
rates of cardiometabolic specialty prescribing in the cohort of patients with schizophrenia, 
further studies may wish to elaborate on whether this is appropriate in this population.
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Prescribing outside of a provider’s area of specialty was common in each of the cohorts and 
appeared more common in patients with SMI. In the schizophrenia cohort specifically, 
28.8% of antipsychotic prescriptions were written by a PCP, and psychiatric specialists 
prescribed medications for hypertension, hyperlipidemia, and diabetes 10.3%, 8.5%, and 
9.2% of the time, respectively. Similarly, in patients with depression, 43.6% of 
antidepressants were provided by PCPs, while psychiatric specialists prescribed fewer than 
3% of each of the medications for cardiometabolic conditions in this cohort. Few studies 
have examined the issue of prescribing medications outside of an area of specialty, so it is 
unclear whether such prescribing puts Medicaid enrollees at risk for adverse events. A study 
by Mark, Levit and Buck showed that 49% of antipsychotic medications and 21% of 
antidepressants dispensed in the U.S. were provided by a psychiatrist, while general 
practitioners provided 22% and 62% of these medications, respectively (30). To our 
knowledge, this is the first study to examine prescribing across areas of specialty in patients 
using medications for both SMI and cardiometabolic health conditions. These findings 
suggest a potential benefit to providing additional training to PCPs in the management of 
mental health conditions and to psychiatric specialists in the management of cardiometabolic 
conditions and the medications used to manage them. Future research should examine 
whether such prescribing impacts patient outcomes.
A number of limitations should be highlighted. Given the cross-sectional nature of this 
study, no causal inferences between appropriateness of prescribing and the number of 
prescribers can be made. In addition, there was missing information related to prescriber 
type for some prescriptions that we imputed, which may have been misattributed. Our results 
are limited to prescribing among the specific subset of chronic CMCs examined and may not 
reflect the full number of conditions or prescribers involved in the care of these individuals. 
Finally, these results can only be generalized to conditions we studied in the context of four 
state Medicaid programs and may not generalize to individuals outside of the Medicaid 
program or to individuals enrolled in managed care Medicaid programs or dually enrolled in 
Medicare.
This study also has a number of strengths. To our knowledge, this is first study to examine 
prescriber continuity in patients with cardiometabolic conditions with and without SMI. In 
addition, this study examines continuity of prescribing across multiple states’ Medicaid 
programs and conditions. In summary, the results of this study suggest that few patients 
receive all of their prescriptions from a single prescriber, many patients receive prescriptions 
from specialty providers, and providers are likely to prescribe medications outside of their 
area of specialty. Although additional research is needed to better understand health 
outcomes from discordant prescribing observed in this study, the results have implications to 
a number of different groups. In particular, clinicians should be cognizant of the potential for 
prescribing by other providers to reduce the risk of medication interactions, therapeutic 
duplications, and other adverse drug events. This may also argue for care management and 
the involvement of clinical pharmacist support to monitor and address adverse drug events 
should they arise (31).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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